In 2023, Jiangsu Hengrui Pharmaceuticals conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Waste Recovered | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Hazardous Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Non-Hazardous Waste Disposed | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected waste data points. To access the complete dataset with full disclosures and structure, create a free account to purchase the full dataset.
In 2023, Jiangsu Hengrui Pharmaceuticals generated a total of 18,931 metric tonnes of waste.
Of this amount, 97.69% of Jiangsu Hengrui Pharmaceuticals's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 2.31% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.
Since 2021, Jiangsu Hengrui Pharmaceuticals's total waste generation increased by 29.42%, including a 30.96% rise in 2023, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.
Over the same period, Jiangsu Hengrui Pharmaceuticals's hazardous waste share remained stable both over the long term and in 2023, reflecting consistent but static performance in managing hazardous materials.
Overall, Jiangsu Hengrui Pharmaceuticals is producing more waste without a change in hazardousness, implying that operational growth is not being accompanied by stronger safeguards against environmental and human health risks.